Application of composition containing Jiangsan in preparation of medicine for preventing or treating inflammatory bowel disease

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to application of a composition containing Jiangsan in preparation of medicines for preventing or treating inflammatory bowel diseases. The invention systematically reveals the obvious curative effect of the Jiangsan in improving the inflammatory bowel disease of mice for the first time. Through cell and animal experiments, the invention verifies that the Jiangjing powder has a remarkable anti-inflammatory effect on lipopolysaccharide-induced Caco-2 cell inflammation and DSS-induced inflammatory bowel disease mouse models. The Jiang powder reduces intestinal injury by reducing release of inflammatory factors. The pharmacological activities of anti-inflammation, immunoregulation and the like of the Jiangsan are fully exerted, a safe and effective innovative treatment choice is provided, the Jiangsan has the development potential as functional food, dietary supplement or candidate medicine, and a new thought and strategy are provided for prevention and treatment of patients with inflammatory bowel diseases. The research blank of the traditional Chinese medicine Jiangsan in treatment of the inflammatory bowel disease is filled, and the Jiangsan has remarkable technical innovation and application prospects.

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to an application of a composition comprising Jiming Powder in the preparation of a drug for preventing or treating inflammatory bowel disease. Background Art

[0002] Inflammatory bowel disease (IBD) is a chronic inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), of which UC is the most common type. The main symptoms of IBD include diarrhea, bloody stools with mucus, and abdominal pain, which seriously affect the patient's quality of life and work status. Due to the lack of specific drugs, the treatment process of IBD is often long and prone to relapse. Even if the disease is controlled, patients need to take medication for a long time, which causes a heavy economic burden. The drugs used in the treatment of IBD mainly include mesalazine preparations (such as 5-aminosalicylic acid and sulfasalazine), glucocorticoids (such as methylprednisolone), immunosuppressants (such as azathioprine), and anti-inflammatory drugs (such as levofloxacin). These drugs can relieve the symptoms of IBD or slow down the progression of the disease, but their efficacy is limited and they are prone to induce toxic side effects. Traditional Chinese medicine has shown potential therapeutic effects in improving intestinal mucosal barrier function, regulating immunity and antioxidant effects, and restoring intestinal flora homeostasis.

[0003] IBD is a chronic inflammatory disease with unclear etiology. Traditional Chinese medicine classifies it into categories such as "blood in stool", "intermittent diarrhea", "chronic diarrhea" and "intestinal wind". According to the diagnostic basis of the "Expert Consensus on Diagnosis and Treatment of Ulcerative Colitis in Traditional Chinese Medicine (2017)", IBD is divided into seven syndromes: liver depression and spleen deficiency syndrome, large intestine damp-heat syndrome, heat toxicity syndrome, yin-blood deficiency syndrome, cold-heat syndrome, spleen deficiency and dampness accumulation syndrome, and spleen-kidney yang deficiency syndrome. Among them, large intestine damp-heat syndrome is the most common syndrome in clinical traditional Chinese medicine. Inflammatory cytokines such as TNF-α, IL-6, and IL-1β play an important role in the pathogenesis of large intestine damp-heat syndrome IBD, which can reflect the course and severity of the disease. The effect of treating large intestine damp-heat syndrome IBD can be achieved by inhibiting the expression of TNF-α, IL-6, and IL-1β. The Chinese medicine compound "Tongxie Yaofang combined with Sijunzi Decoction" has the main effects of removing dampness and stopping diarrhea, soothing the liver and strengthening the spleen. Studies have found that the use of this compound to treat diarrhea-type irritable bowel syndrome can effectively reduce the level of proinflammatory factor TNF-α and increase the level of anti-inflammatory factor IL-10, and can also effectively improve symptoms such as abdominal pain, abdominal distension, and diarrhea. "Wumei Pills", which has the effects of warming the kidney and strengthening the spleen, clearing heat and drying dampness, can play a therapeutic role in UC by reducing the serum TNF-α level and increasing the IL-10 level of UC model rats. In summary, the Chinese medicine compound with the effect of removing dampness can alleviate IBD symptoms by regulating the body's inflammatory response.

[0004] Jiming San (Ji-Ming-San, JMS) comes from "Zhengzhi Zhunsheng" and is a typical prescription that should be used at the right time. It is named because the best time to take the medicine is "dawn when the cock crows". The prescription is composed of 15g of betel nut, 30g of dried tangerine peel, 30g of papaya, 6g of evodia rutaecarpa, 9g of perilla, 15g of platycodon, and 15g of ginger. It has the effects of removing dampness and turbidity, promoting qi and relieving depression, and unblocking meridians and removing stagnation. It is mainly used clinically to treat dampness, swelling, beriberi, rheumatic rheumatism, gout and bursitis. Modern pharmacological studies have found that Jiming San has anti-inflammatory, anticoagulant, diuretic, analgesic and sedative effects. In terms of anti-inflammatory, Jimingsan extract can reduce inflammatory responses such as acute swelling, chondrocyte degradation and painful paw edema in rat osteoarthritis models; Jimingsan extract can downregulate the protein expression of iNOS, COX-2 and MMP-13 in macrophages, and inhibit the production of inflammatory mediators NO and PGE2 in a dose-dependent manner. Although studies have found that Jimingsan has an intervention effect on a variety of inflammatory diseases, its potential in the treatment of inflammatory bowel disease has not been fully studied. Summary of the invention

[0005] In view of the deficiencies of the prior art, the present invention provides an application of a composition comprising Jiming Powder in the preparation of a drug for preventing or treating inflammatory bowel disease. The present invention clarifies the application of a composition comprising Jiming Powder in the preparation of a drug for preventing and / or treating inflammatory bowel disease, aiming to give full play to the anti-inflammatory, immunomodulatory and other pharmacological activities of Jiming Powder, provide a novel and effective treatment option for patients with inflammatory bowel disease, and provide new ideas and strategies for the prevention and treatment of inflammatory bowel disease.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] The first object of the present invention is to provide a composition comprising Jimingsan for use in preparing a drug for preventing or treating inflammatory bowel disease.

[0008] Preferably, the composition containing Jiming Powder is prepared from the following raw materials in parts by weight: 19-21 parts of betel nut, 21-39 parts of tangerine peel, 21-39 parts of papaya, 2-12 parts of Evodia rutaecarpa, 4-16 parts of Perilla frutescens, 9-21 parts of Platycodon grandiflorum and 9-21g of ginger.

[0009] Preferably, the preparation method of the composition containing Jimingsan comprises:

[0010] The prepared Chinese medicinal slices of Jiming Powder are soaked in 8-12 times the volume of pure water for 0.5-2 hours, boiled over high heat, and then simmered over low heat for 0.5-2 hours. The residue is filtered to collect the medicinal liquid, and then water is added for further decocting. The decoction is repeated 1-2 times, and finally the medicinal liquids are combined for rotary evaporation concentration. The concentrated liquid is precipitated with ethanol, and the supernatant solution is collected for concentration and freeze-drying into powder, which is then stored in the freezer.

[0011] Preferably, the inflammatory bowel disease includes ulcerative colitis and Crohn's disease.

[0012] Preferably, the drug is mixed with a pharmaceutically acceptable excipient to form any clinically or pharmaceutically acceptable dosage form.

[0013] Preferably, the dosage forms include tablets, capsules, granules, powders, powder injections, pills, emulsions, suspensions, solutions, sprays, patches and sublingual tablets.

[0014] Preferably, the drug is mixed with pharmaceutically acceptable excipients to form an oral dosage form.

[0015] Compared with the prior art, the present invention has the following beneficial effects:

[0016] The present invention provides a new use of Jiming Powder, a new application of a composition whose active ingredient is Jiming Powder in the preparation of drugs for preventing and / or treating inflammatory bowel disease. The present invention systematically reveals for the first time the significant therapeutic effect of Jiming Powder in improving inflammatory bowel disease in mice, and verifies the significant anti-inflammatory effect of Jiming Powder on lipopolysaccharide-induced Caco-2 cell inflammation and DSS-induced inflammatory bowel disease mouse model through cell and animal experiments. Jiming Powder reduces intestinal damage by reducing the release of inflammatory factors. The present invention gives full play to the pharmacological activities of Jiming Powder, such as anti-inflammatory and immunomodulatory, and provides a safe and effective innovative treatment option. It has the potential for development as a functional food, dietary supplement or candidate drug, and provides new ideas and strategies for the prevention and treatment of patients with inflammatory bowel disease.

[0017] Secondly, Jimingsan is composed of traditional Chinese medicine, which has the advantages of less toxic side effects and stable efficacy in the overall treatment and maintenance stages, and the traditional Chinese medicine has many active ingredient targets and unique advantages. The present invention fills the research gap of traditional Chinese medicine Jimingsan in the treatment of inflammatory bowel disease, and has significant technical innovation and application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 This is a graph showing the results of a study on the effect of Jimingsan on the weight changes of mice with inflammatory bowel disease;

[0019] Figure 2 This is a graph showing the research results on the effect of Jimingsan on the DAI score of mice with inflammatory bowel disease;

[0020] Figure 3This is a graph showing the results of a study on the effects of Jimingsan on the colon of mice with inflammatory bowel disease;

[0021] Figure 4 This is a graph showing the results of a study on the effect of Jimingsan on colon length in mice with inflammatory bowel disease;

[0022] Figure 5 This is a graph showing the results of a study on the effect of Jimingsan on the activity of myeloperoxidase (MPO) in the colon of mice with inflammatory bowel disease;

[0023] Figure 6 This is a graph showing the results of a study on the effects of Jimingsan on colon inflammatory factors in mice with inflammatory bowel disease;

[0024] Figure 7 This is a study result showing the effect of Jimingsan on H&E staining of the colon in mice with inflammatory bowel disease;

[0025] Figure 8 This is a graph showing the results of a study on the effect of Jimingsan on colon tissue pathology scores in mice with inflammatory bowel disease;

[0026] Fig. 9 This is a graph showing the research results of the effect of Jimingsan on the survival rate of Caco2 cells;

[0027] Fig.10 This is a graph showing the research results on the effects of Jimingsan on inflammatory factors in the Caco2 cell model induced by lipopolysaccharide. DETAILED DESCRIPTION

[0028] The above contents of the present invention are further described in detail below by means of specific implementation methods in the form of examples, but this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples.

[0029] Unless otherwise specified, the reagents used in the present invention are all conventional reagents, and the corresponding experimental operation methods and detection methods are all from conventional operation guidelines.

[0030] 1. Reagents and raw materials

[0031] The 3% DSS (dextran sulfate sodium) was purchased from Shanghai Aichun Biotechnology Co., Ltd., model 9011-18-1;

[0032] All the raw medicinal materials used in the embodiments of the present invention are provided by Guangdong Provincial Hospital of Traditional Chinese Medicine, China;

[0033] The hematoxylin and eosin (H&E) staining kit was purchased from Wuhan Saiweier Biotechnology Co., Ltd., model G1003.

[0034] Example 1 Preparation of Jiming Powder of the Present Invention

[0035] Recipe: Jiming Powder is composed of 9g of Perilla, 30g of papaya, 15g of betel nut, 6g of Evodia rutaecarpa, 30g of tangerine peel, 15g of Platycodon grandiflorum, and 15g of ginger.

[0036] Preparation method: soak the Chinese herbal medicine slices of the above formula in 10 times the volume of pure water for 1 hour, boil over high heat, and then simmer over low heat for 1 hour. Filter the residue to collect the medicinal liquid and continue to add water to boil, decoct once more, and finally combine the two medicinal liquids for rotary evaporation concentration. Precipitate the concentrated liquid with 60% ethanol, collect the supernatant solution, concentrate it and freeze-dry it into powder, and store it in a -80℃ refrigerator for use.

[0037] Example 2 Preparation of Jiming Powder of the Present Invention

[0038] Recipe: Jiming Powder is composed of 4g of Perilla, 21g of Papaya, 9g of Areca Nut, 2g of Evodia rutaecarpa, 39g of Tangerine Peel, 9g of Platycodon, and 9g of Ginger.

[0039] Preparation method: soak the Chinese herbal medicine slices of the above formula in 10 times the volume of pure water for 1 hour, boil over high heat, and then simmer over low heat for 1 hour. Filter the residue to collect the medicinal liquid and continue to add water to boil, decoct once more, and finally combine the two medicinal liquids for rotary evaporation concentration. Precipitate the concentrated liquid with 60% ethanol, collect the supernatant solution, concentrate it and freeze-dry it into powder, and store it in a -80℃ refrigerator for use.

[0040] Example 3 Preparation of Jiming Powder of the Present Invention

[0041] Recipe: Jiming Powder is composed of 16g ​​of Perilla, 39g of papaya, 21g of betel nut, 12g of Evodia rutaecarpa, 39g of tangerine peel, 21g of Platycodon grandiflorum, and 21g of ginger.

[0042] Preparation method: soak the Chinese herbal medicine slices of the above formula in 10 times the volume of pure water for 1 hour, boil over high heat, and then simmer over low heat for 1 hour. Filter the residue to collect the medicinal liquid and continue to add water to boil, decoct once more, and finally combine the two medicinal liquids for rotary evaporation concentration. Precipitate the concentrated liquid with 60% ethanol, collect the supernatant solution, concentrate it and freeze-dry it into powder, and store it in a -80℃ refrigerator for use.

[0043] Example 4 Preparation of Jiming Powder of the Present Invention

[0044] Recipe: Jiming Powder is composed of 12g of Perilla, 33g of papaya, 18g of betel nut, 15g of Evodia rutaecarpa, 33g of tangerine peel, 18g of Platycodon grandiflorum, and 18g of ginger.

[0045] Preparation method: soak the Chinese herbal medicine slices of the above formula in 10 times the volume of pure water for 1 hour, boil over high heat, and then simmer over low heat for 1 hour. Filter the residue to collect the medicinal liquid and continue to add water to boil, decoct once more, and finally combine the two medicinal liquids for rotary evaporation concentration. Precipitate the concentrated liquid with 60% ethanol, collect the supernatant solution, concentrate it and freeze-dry it into powder, and store it in a -80℃ refrigerator for use.

[0046] Experiment 1: Study on the effect of Jimingsan on improving the phenotype of mice with inflammatory bowel disease

[0047] The present invention uses an ulcerative colitis animal model induced by DSS (dextran sulfate sodium). DSS can damage the tight junctions and basement membranes of colonic epithelial cells, thereby increasing intestinal permeability, causing intestinal flora and other antigens to enter the submucosal layer and systemic circulation, activating immune inflammatory responses, and inducing colitis symptoms. The use of DSS can cause mice to show diarrhea, abdominal pain, and bloody stools, showing an inflammatory bowel disease phenotype similar to that of humans. Therefore, this model conforms to the current phenomenological model of human inflammatory bowel disease.

[0048] In this experiment, the animals used were healthy male mice of the C57BL / 6 strain aged 8-10 weeks, purchased from Guangzhou Ruige Biotechnology Co., Ltd. All mice were kept in an SPF-grade environment with 12 hours of light / 12 hours of darkness (6:00 am to 18:00 pm as the light period) and a temperature of 22-25°C. First, all experimental mice were allowed to undergo a 7-day environmental adaptation period, during which standard feed and purified water were provided. After the adaptation period, the mice were randomly divided into two groups: an inflammatory bowel disease model group and a Jimingsan administration group (8 mice in each group).

[0049] Experimental samples: 3% DSS (dextran sulfate sodium) and Jimingsan prepared in Example 1 of the present invention.

[0050] Inflammatory bowel disease model group: 3% DSS dissolved in a water bottle was given, and the water was changed every two days for 7 days. The weight changes were recorded. When the mice showed obvious diarrhea, intestinal bleeding and weight loss, the model was successfully established.

[0051] Jimingsan group: 3% DSS dissolved in water bottle was given, and the water was changed every two days for 7 days. The Jimingsan dosage was converted to 9.1 times the clinical dosage, and the Jimingsan dosage for mice was calculated to be 14.3 g·kg per day. -1 The Jimingsan freeze-dried powder prepared in Example 1 of the present invention was prepared into a 1.43 g / mL Jimingsan solution using ultrapure water as a solvent. The Jimingsan solution was administered to mice at a fixed time point every day, once a day, and the weight changes of the mice were recorded.

[0052] After the modeling was completed, the mice were killed and the colon and other tissue samples were collected for DAI (Disease Activity Index) scoring, H&E staining, histopathological scoring, MPO activity detection and qPCR detection.

[0053] (1) Disease Activity Index (DAI) Scoring Method (Table 1): From the first day of modeling to the end of the experiment, the weight loss of mice, stool viscosity, and stool bleeding are jointly judged to intuitively determine whether the animal modeling is successful. The final score of DAI depends on the following three scoring criteria. The score obtained for each scoring criterion is judged separately, and finally the average of the three scores is taken as the final DAI score, which is used to judge the severity of colitis in experimental mice.

[0054] Table 1 DAI score table

[0055] score Percentage of weight loss Stool consistency Fecal occult blood 0 0 normal Negative 1 1％～5％ Soft stools Light blue 2 5％～10％ Mucoid stool blue 3 10％～20％ Thin liquid stool Dark Blue 4 ＞20％ － Naked bloody stool

[0056] (2) H&E staining: Colon tissues were fixed in 4% paraformaldehyde and then sequentially dehydrated with graded alcohol, transparentized with xylene, embedded in wax, prepared for paraffin sections, dewaxed and stained (stained with hematoxylin, washed with water, and stained with eosin), dehydrated with graded ethanol, transparentized, and sealed (sealed with neutral gum). The tissues were observed under a microscope and photographed using an imaging system, and their histopathological scores were performed.

[0057] (3) Histopathological scoring: Colon tissue was fixed with 4% paraformaldehyde, embedded in paraffin, and stained with H&E. Histopathology was scored based on six indicators: goblet cell reduction, intestinal mucosal thickening, inflammatory cell infiltration, submucosal cell infiltration, ulcer (epithelial cell surface), and abscess. Each indicator was scored as 1 to 3 points or 1 to 4 points, and the final score was the sum of the six scores (0 to 20 points).

[0058] (4) MPO detection: After colon tissue homogenization, centrifugation was performed to obtain the supernatant, and the neutrophil infiltration was detected using an MPO kit (purchased from Beijing Solebow Technology Co., Ltd., model BC5715).

[0059] (5) qPCR detection: RNA was extracted from colon tissue samples using AG RNAex Pro RNA extraction reagent (purchased from Hunan Aikerui Biotechnology Co., Ltd., model AG21102), and then mRNA was reverse transcribed into cDNA using HiScript IIQ RT SuperMix for qPCR kit (purchased from Nanjing Novozyme Biotechnology Co., Ltd., model R223-01). qPCR reaction was performed using ChamQ SYBR qPCR Master Mix (purchased from Nanjing Novozyme Biotechnology Co., Ltd., model Q311-02). The reaction system is shown in Table 2 below, and the reaction procedure is: denaturation at 95°C for 5 minutes, denaturation at 95°C for 15 seconds, annealing at 60°C for 30 seconds, extension at 72°C for 30 seconds, and 40 cycles.

[0060] Table 2 qPCR reaction system

[0061] system dose cDNA 1 μg SYBR Green / Flourescein qPCR Master Mix 5μL Upstream and downstream primer mixture (2μM) 2μL DEPC water Complementary reaction system Final volume 10μL

[0062] Gapdh gene was used as internal reference and the -ΔΔCT The relative expression of target genes in tissues was calculated by qPCR analysis. The primer sequences for qPCR analysis are shown in Table 3.

[0063] Table 3 qPCR analysis primer sequences

[0064]

[0065]

[0066] The experimental results are as follows Figure 1 to Figure 6 The results showed that compared with the inflammatory bowel disease model group, the inflammatory bowel disease mice in the Jimingsan group had a lower weight loss ( Figure 1 ), lower disease activity index (DAI) score ( Figure 2 ), a longer colon ( Figures 3-4 ), lower myeloperoxidase activity (MPO) ( Figure 5 ) and lower inflammatory factors ( Figure 6 ), which showed that Jiming Powder alleviated the symptoms of experimental inflammatory bowel disease. Histological examination confirmed that the inflammatory bowel disease in the Jiming Powder group was milder, with milder neutrophil infiltration, milder mucosal shedding, and fewer ulcers ( Figures 7-8 ).

[0067] In summary, Jimingsan has an improving effect on the phenotype of inflammatory bowel disease in mice.

[0068] Experiment 2: Study on the effect of Jimingsan on LPS-induced Caco2 cell inflammation

[0069] Lipopolysaccharides (LPS) are a unique component of the cell wall of Gram-negative bacteria, also known as endotoxin. After infecting the host, it can cause sepsis, septic shock and multiple organ dysfunction syndrome. LPS can induce the host's response through the signal transduction pathway, stimulate immune cells to produce a large number of inflammatory cytokines with pyrogenic effects, and cause overactivation of the immune system. At the same time, LPS can activate the NF-κB signaling pathway, thereby further promoting the expression of inflammatory factors such as TNF-α, IL-6, IL-1β, etc. Therefore, LPS is often used as an activator of the NF-κB signaling pathway and is also often used as a model substance for inducing Caco-2 cell inflammation. The Caco-2 cell model can not only simulate the barrier function of the small intestine epithelium, but also study the changes in the immune response and barrier function of the cells in an in vitro environment, providing a reliable model for studying the absorption mechanism of the intestine. The use of LPS to construct a Caco-2 cell inflammation model is a common method for studying in vitro inflammation models.

[0070] In this experiment, the CCK8 method was used to detect the effect of different concentrations of Jiming Powder on the survival rate of Caco2 cells, and the qPCR detection method was used to explore the effect of Jiming Powder on the lipopolysaccharide-induced Caco2 cell inflammation model. The Jiming Powder lyophilized powder prepared in Example 1 of the present invention was used as the experimental sample and ultrapure water was used as the solvent to prepare a Jiming Powder solution of corresponding concentration for the experiment.

[0071] (1) CCK8 assay to detect the effects of different concentrations of Jimingsan on the survival rate of Caco2 cells

[0072] Caco2 cells (1×10 4 ) were inoculated in 96-well plates and incubated with Jimingsan (0, 25 μg / mL JMS, 50 μg / mL JMS, 100 μg / mL JMS) for 24 h. 10 μl CCK-8 was added, and after incubation for 12 h, the cell absorbance was measured at 450 nm using a Synergy HT multi-mode microplate reader.

[0073] Lipopolysaccharide-induced Caco2 cell inflammation model: Caco2 cells were divided into a normal group, a model group, and a Jimingsan-administered group. The normal group was placed in a 37°C cell culture incubator (containing 5% carbon dioxide) under normal conditions and cultured with DMEM medium (containing 10% FBS) without LPS stimulation. The other groups were given LPS (200 μg·L -1 ) for 24 hours, the normal group and the model group were cultured for another 24 hours, and the Jimingsan group was treated with 25μg / mL JMS, 50μg / mL JMS, and 100μg / mL JMS for 24 hours, respectively, and mRNA was extracted for subsequent experiments. The mRNA expression of inflammatory factors (such as TNF-α, IL-6, and IL-1β) was detected by real-time quantitative PCR (qPCR), and the expression levels of inflammatory factors between the normal group and the LPS-induced group were compared to determine whether the lipopolysaccharide-induced Caco2 cell inflammation model was successfully established.

[0074] (2) qPCR: After RNA is extracted from cell samples, PrimeScript TM RT Master Mix Kit was used to reverse transcribe mRNA into cDNA. qPCR Master Mix was used for qPCR reaction. The reaction system is as follows:

[0075] 1μg cDNA, 5μL SYBR Green / Flourescein qPCR Master Mix and 2μL upstream and downstream primer mixture (2μM), add DEPC water to make up the reaction system, the final volume is 10μL. The reaction program is: 95℃ denaturation for 5 minutes, 95℃ denaturation for 15 seconds, 60℃ annealing for 30 seconds, 72℃ extension for 30 seconds, and 40 cycles. Gapdh gene was used as the internal reference, according to 2 -ΔΔCT The relative expression of the target gene in the cells was calculated by qPCR analysis. The primer sequences for qPCR analysis are shown in Table 4.

[0076] Table 4 Primer sequences for qPCR analysis

[0077]

[0078] The experimental results are as follows Figure 9-10 The results showed that administration of Jimingsan at different concentrations had no significant effect on the proliferation of Caco2 cells ( Fig. 9 ), and can significantly reduce the expression of inflammatory factors in Caco2 cells induced by LPS ( Fig.10 ).

[0079] In summary, the present invention systematically reveals for the first time the significant therapeutic effect of Jimingsan in improving inflammatory bowel disease in mice. Through cell and animal experiments, the present invention verifies the significant anti-inflammatory effect of Jimingsan on lipopolysaccharide-induced Caco-2 cell inflammation and DSS-induced inflammatory bowel disease mouse model. Jimingsan reduces intestinal damage by reducing the release of inflammatory factors. The present invention gives full play to the anti-inflammatory, immunomodulatory and other pharmacological activities of Jimingsan, provides a safe and effective innovative treatment option, has the potential for development as a functional food, dietary supplement or candidate drug, and provides new ideas and strategies for the prevention and treatment of patients with inflammatory bowel disease. The present invention fills the research gap of the traditional Chinese medicine Jimingsan in the treatment of inflammatory bowel disease, and has significant technical innovation and application prospects.

[0080] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by a person of ordinary skill in the art without departing from the spirit and technical concept disclosed by the present invention shall still be covered by the claims of the present invention.

Claims

1. Use of a composition comprising Jimingsan in the preparation of a drug for preventing or treating inflammatory bowel disease.

2. The use according to claim 1, characterized in that: The composition containing Jimingsan is prepared by including the following raw materials in parts by weight: 19-21 parts of betel nut, 21-39 parts of tangerine peel, 21-39 parts of papaya, 2-12 parts of evodia rutaecarpa, 4-16 parts of perilla, 9-21 parts of platycodon and 9-21g of ginger.

3. The use according to claim 1, characterized in that: The preparation method of the composition containing Jimingsan comprises: The prepared Chinese medicinal slices of Jiming Powder are soaked in 8-12 times the volume of pure water for 0.5-2 hours, boiled over high heat, and then simmered over low heat for 0.5-2 hours. The residue is filtered to collect the medicinal liquid, and then water is added for further decocting. The decoction is repeated 1-2 times, and finally the medicinal liquids are combined for rotary evaporation concentration. The concentrated liquid is precipitated with ethanol, and the supernatant solution is collected for concentration and freeze-drying into powder, which is then stored in the freezer.

4. The use according to claim 1, characterized in that: The inflammatory bowel diseases include ulcerative colitis and Crohn's disease.

5. The use according to claim 1, characterized in that: The drug is mixed with pharmaceutically acceptable excipients to prepare any clinically or pharmaceutically acceptable dosage form.

6. The use according to claim 5, characterized in that: The dosage forms include tablets, capsules, granules, powders, powder injections, pills, emulsions, suspensions, solutions, sprays, patches and sublingual tablets.

7. The use according to claim 1, characterized in that: The drug is mixed with pharmaceutically acceptable excipients to prepare an oral dosage form.

Images